Flow cytometry evaluation of erythroid dysplasia in pat syndrome

Leukemia

20, 549-555

DOI: 10.1038/sj.leu.2404142

Citation Report

#	Article	IF	Citations
1	The Role of Flow Cytometric Immunophenotyping in Myelodysplastic Syndromes. Annals of the New York Academy of Sciences, 2006, 1089, 383-394.	1.8	11
2	Assessment of erythrocyte shape by flow cytometry techniques. Journal of Clinical Pathology, 2006, 60, 549-554.	1.0	62
3	Multiparametric Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes and Related Disorders. Laboratory Medicine, 2007, 38, 305-313.	0.8	5
4	Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2007, 25, 3503-3510.	0.8	969
5	RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood, 2007, 109, 3552-3559.	0.6	156
6	A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques. Cancer Treatment Reviews, 2007, 33, S31-S41.	3.4	1
7	Myeloid Malignancies: Myelodysplastic Syndromes, Myeloproliferative Disorders, and Acute Myeloid Leukemia. Clinics in Laboratory Medicine, 2007, 27, 551-575.	0.7	72
8	21 Immunophenotypic analysis of myelodysplastic syndromes. Leukemia Research, 2007, 31, S12-S13.	0.4	0
10	Diagnostic flow cytometry for lowâ€grade myelodysplastic syndromes. Hematological Oncology, 2008, 26, 193-198.	0.8	33
11	Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls. Leukemia Research, 2008, 32, 215-224.	0.4	82
12	Recent advances in the understanding of inherited sideroblastic anaemia. British Journal of Haematology, 2008, 143, 27-38.	1.2	68
13	Increased Apoptosis as a Mechanism of Ineffective Erythropoiesis in Myelodysplastic Syndromes. Clinical Leukemia, 2008, 2, 113-120.	0.2	4
14	Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Human Molecular Genetics, 2008, 18, 1-11.	1.4	128
15	The Role of Flow Cytometry in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 935-941.	2.3	11
17	SÃndromes mielodisplÃ¡sicas: aspectos moleculares, laboratoriais e a classificaÃ§Ã£o OMS 2008. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 463-470.	0.7	2
19	The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer, 2009, 115, 4524-4532.	2.0	23
20	Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis. International Journal of Laboratory Hematology, 2009, 31, 479-483.	0.7	17
21	The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study. Leukemia Research, 2009, 33, 1039-1046.	0.4	51

#	Article	IF	Citations
22	Ferritin for the clinician. Blood Reviews, 2009, 23, 95-104.	2.8	433
23	Ferritins: A family of molecules for iron storage, antioxidation and more. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 589-599.	1.1	718
24	The role of iron in mitochondrial function. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 629-636.	1.1	151
25	Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica, 2009, 94, 1066-1074.	1.7	135
26	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 2009, 114, 937-951.	0.6	3,864
27	Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment. Seminars in Hematology, 2009, 46, 371-377.	1.8	81
28	The Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2009, 23, 675-691.	0.9	25
29	Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica, 2009, 94, 1160-1163.	1.7	28
30	Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica, 2009, 94, 1041-1043.	1.7	5
31	Myelodysplastic syndrome: classification and prognostic systems. Oncology Reviews, 2010, 4, 25-33.	0.8	7
32	Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry Part B - Clinical Cytometry, 2010, 78B, 154-168.	0.7	53
33	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. , 0, , 307-328.		0
34	CD71 (Transferrin Receptor). American Journal of Clinical Pathology, 2010, 134, 429-435.	0.4	94
35	Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 783-792.	1.1	248
36	Diagnostic Tools in the Indications for Allogeneic Stem Cell Transplantation in Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2010, 16, 1-11.	2.0	18
37	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2010, 16, 1187-1211.	2.0	76
38	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 2011, 118, 6239-6246.	0.6	457
39	Role of flow cytometry in diagnostics of myelodysplastic syndromesâ€"beyond the WHO 2008 classification. Seminars in Diagnostic Pathology, 2011, 28, 273-282.	1.0	20

#	Article	IF	Citations
40	Heme-Oxygenases during Erythropoiesis in K562 and Human Bone Marrow Cells. PLoS ONE, 2011, 6, e21358.	1.1	21
41	CD71 is Selectively and Ubiquitously Expressed at High Levels in Erythroid Precursors of All Maturation Stages. American Journal of Surgical Pathology, 2011, 35, 723-732.	2.1	77
42	Ring sideroblasts and sideroblastic anemias. Haematologica, 2011, 96, 789-792.	1.7	64
43	Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2011, 96, 349-352.	1.7	20
44	Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leukemia Research, 2011, 35, 1605-1610.	0.4	10
45	Classification and Prognostic Evaluation of Myelodysplastic Syndromes. Seminars in Oncology, 2011, 38, 627-634.	0.8	71
46	Immunophenotypic signatures of benign and dysplastic granulopoiesis by cytomic profiling. Cytometry Part B - Clinical Cytometry, 2011, 80B, 282-290.	0.7	8
47	Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. Cytometry Part B - Clinical Cytometry, 2011, 80B, 201-211.	0.7	40
48	Clinical Utility of Flow Cytometry in the Study of Erythropoiesis and Nonclonal Red Cell Disorders. Methods in Cell Biology, 2011, 103, 311-332.	0.5	9
49	Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. Haematologica, 2011, 96, 1424-1432.	1.7	31
52	H-ferritin overexpression promotes radiation-induced leukemia/lymphoma in mice. Carcinogenesis, 2012, 33, 2269-2275.	1.3	13
53	Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica, 2012, 97, 895-902.	1.7	29
54	Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica, 2012, 97, 1209-1217.	1.7	136
55	Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. Leukemia Research, 2012, 36, 1229-1236.	0.4	16
57	Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 2012, 26, 1730-1741.	3.3	217
58	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 2012, 26, 1908-1975.	3.3	738
60	Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 2013, 27, 1981-1987.	3.3	78
61	Immunophenotypic profile of nucleated erythroid progenitors during maturation in regenerating bone marrow. Leukemia and Lymphoma, 2013, 54, 2523-2530.	0.6	60

#	Article	IF	Citations
62	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood, 2013, 121, 260-269.	0.6	124
63	How I manage patients with atypical microcytic anaemia. British Journal of Haematology, 2013, 160, 12-24.	1.2	40
64	Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. British Journal of Haematology, 2013, 161, 726-737.	1.2	10
65	CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias. American Journal of Clinical Pathology, 2013, 140, 370-378.	0.4	17
66	Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling. Blood Cancer Journal, 2013, 3, e100-e100.	2.8	28
67	Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica, 2013, 98, 420-423.	1.7	51
68	Cutting Edge: Flow Cytometry in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 892-902.	2.3	22
69	Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. Haematologica, 2014, 99, e8-e10.	1.7	16
70	Assessment of erythroid dysplasia by â€œdifference from normalâ€•in routine clinical flow cytometry work-up. , 2014, , n/a-n/a.		15
71	Descriptive analysis of antigen expression pattern in refractory anemia, refractory anemia with ringed sideroblasts and refractory anemia with excess blast cases using flow cytometry. Journal of Medicine and Biomedical Sciences, 2014, 4, 49-56.	0.0	0
72	Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment. Leukemia and Lymphoma, 2014, 55, 749-760.	0.6	9
73	Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leukemia and Lymphoma, 2014, 55, 892-898.	0.6	45
74	Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation. International Journal of Laboratory Hematology, 2014, 36, 184-196.	0.7	37
75	Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Archives of Toxicology, 2014, 88, 1787-1802.	1.9	135
76	Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromesâ€”proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia, 2014, 28, 1793-1798.	3.3	124
77	Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes. Cardiovascular & Hematological Disorders Drug Targets, 2015, 15, 148-161.	0.2	1
78	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 472-478.	1.7	28
79	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	1.7	38

#	Article	IF	Citations
80	Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?. Current Hematologic Malignancy Reports, 2015, 10, 309-317.	1.2	9
81	Specific Targeting of Proerythroblasts and Erythroleukemic Cells by the VP1u Region of Parvovirus B19. Bioconjugate Chemistry, 2015, 26, 1923-1930.	1.8	18
82	Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis. Leukemia Research, 2015, 39, 361-370.	0.4	18
83	Assessment of erythroid dysplasia by â€œDifference from normalâ€•in routine clinical flow cytometry workup. , 2015, 88, 125-135.		20
84	Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes. European Journal of Haematology, 2015, 94, 519-525.	1.1	2
85	DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017017.	0.5	7
86	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Frontiers in Oncology, 2016, 6, 161.	1.3	22
87	Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. American Journal of Clinical Pathology, 2016, 145, 538-551.	0.4	24
88	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	1.7	74
89	The Construction and Characterization of Mitochondrial Ferritin Overexpressing Mice. International Journal of Molecular Sciences, 2017, 18, 1518.	1.8	18
90	Flow Cytometry of Normal Blood, Bone Marrow and Lymphatic Tissue. , 0, , 36-60.		1
91	Flow Cytometry in Myelodysplastic Syndromes. , 0, , 199-214.		1
92	Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. Leukemia and Lymphoma, 2018, 59, 2242-2245.	0.6	9
93	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica, 2018, 103, 1593-1603.	1.7	49
94	CD105 (Endoglin) as negative prognostic factor in AML. Scientific Reports, 2019, 9, 18337.	1.6	22
95	Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machineâ€learning assisted morphometrics. Cytometry Part B - Clinical Cytometry, 2021, 100, 554-567.	0.7	10
96	Endoglin: An â€˜Accessoryâ€™ Receptor Regulating Blood Cell Development and Inflammation. International Journal of Molecular Sciences, 2020, 21, 9247.	1.8	25
97	Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2020, 98, 399-411.	0.7	24

#	Article	IF	Citations
98	Impact of CD105 Flow-Cytometric Expression on Childhood B-Acute Lymphoblastic Leukemia. Journal of Blood Medicine, 2021, Volume 12, 147-156.	0.7	1
100	Mitochondrial Ferritin: Its Role in Physiological and Pathological Conditions. Cells, 2021, 10, 1969.	1.8	17
101	Blockade of the interaction between BMP9 and endoglin on erythroid progenitors promotes erythropoiesis in mice. Genes To Cells, 2021, 26, 782-797.	0.5	1
102	SÃndrome mielodisplÃ¡sico: aspectos bÃ¡sicos y abordaje diagnÃ³stico. Revista Colombiana De Hematologìa Y Oncologìa, 2021, 8, 90-106.	0.0	0
103	The Flow Cytometric Evaluation of Hematopoietic Neoplasia. , 2011, , 656-673.		3
104	Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes. PLoS ONE, 2014, 9, e88706.	1.1	15
105	H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner. PLoS ONE, 2015, 10, e0139915.	1.1	33
106	Prediction of Progression from Refractory Cytopenia with Unilineage Dysplasia by Analysis of Bone Marrow Blast Cell Composition. Journal of Clinical and Experimental Hematopathology: JCEH, 2012, 52, 63-66.	0.3	4
107	Acute Myeloid Leukemia. , 2010, , 241-280.		0
108	Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. , 2010, , 293-312.		0
112	Flow Cytometry in Myelodysplastic Syndromes. , 2011, , 121-143.		2
113	Identification of CD105 (endoglin) as novel risk marker in CLL. Annals of Hematology, 2022, 101, 773-780.	0.8	4
114	Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study. PLoS ONE, 2022, 17, e0278040.	1.1	0
115	Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues. Cytometry Part B - Clinical Cytometry, 2023, 104, 27-50.	0.7	10